title: Regression of neovascular iris vessels by intravitreal injection of bevacizumab.
authors.affiliation: Retina Consultants of Alabama, Callahan Eye Foundation Hospital, and the University of Alabama at Birmingham School of Medicine, Department of Ophthalmology, Birmingham, Alabama 35233, USA.
authors.forename: John O
authors.initials: JO
authors.lastname: Mason
authors.forename: Michael A
authors.initials: MA
authors.lastname: Albert
authors.forename: Andrew
authors.initials: A
authors.lastname: Mays
authors.forename: Rachel
authors.initials: R
authors.lastname: Vail
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000869:Anterior Eye Segment / Q000098:blood supply; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D015355:Glaucoma, Neovascular / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D007498:Iris / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab